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Background. Leishmaniasis is a tropical disease 
prevalent in developing countries. 
Results: Leishmania major type I nitroreductase 
(LmNTR) metabolises nitroaromatic/quinone 
substrates, an activity essential for parasite 
viability. 
Conclusion: LmNTR exhibits biochemical 
characteristics of its bacterial counterparts and its 
activity is essential for parasite growth. 
Significance: LmNTR can be exploited as a 
prodrug activation enzyme or as a target for 
inhibitor design in drug development. 
 
SUMMARY 
Nitroaromatic prodrugs are used to treat a range 
of microbial infections with selectivity achieved 
by specific activation reactions. For 
trypanosomatid parasites this is mediated by type 
I nitroreductases (NTRs). Here, we demonstrate 
that the causative agent of leishmaniasis, 
Leishmania major, expresses a FMN-containing 
NTR (LmNTR) that metabolises a wide range of 
substrates and based on electron donor and 
acceptor preferences may function as a 
NADH:quinone oxidoreductase. Using gene 
deletion approaches, we demonstrate that this 
activity is essential to L. major promastigotes, 
the parasite forms found in the insect vector. 
Intriguingly, although LmTR
+/-
 heterozygote 
promastigote parasites could differentiate into 
infectious form metacyclic cells, these were 
unable to establish infections in cultured 
mammalian cells and cause delayed pathology in 
mice. Further, we exploit the LmNTR activity 
evaluating a library of nitrobenzylphosphoramide 
mustards using biochemical and phenotypic 
screens. We identify a subset of compounds that 
display significant growth inhibitory properties 
against the intracellular parasite form found in 
the mammalian host. The leishmanicidal activity 
was shown to be LmNTR specific as the 
LmTR
+/-
 heterozygote promastigotes displayed 
resistance to the most potent mustards. We 
conclude that LmNTR can be targeted for drug 
development by exploiting its prodrug activating 
property or by designing specific inhibitors to 
block its endogenous function 
 
Insect transmitted, protozoan parasites 
belonging to the genus Leishmania are 
responsible for a spectrum of diseases known as 
leishmaniasis. These infections are endemic in 88 
countries around the World with approximately 
350 million people living in “at risk” areas (1). 
Recently, as a result of military activity, 
population migration, modern medical practices, 
intravenous drug usage and global warming, 
leishmaniasis has emerged as a problem in non-
endemic areas (2-4). 
 
A vaccine for visceral leishmaniasis is in 
Phase Is trial but currently drugs are the only 
option available to treat leishmanial infections. 
Use of the frontline antimonial-based therapies is 
problematic as they are toxic, clinical resistance 
is on the rise and often require medical 
supervision to administer (5). Recent progress 
has been made in developing new leishmanicidal 
agents with several compounds such as 
amphotericin B, paromomycin and miltefosine 
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coming to market (1). However, there are issues 
associated with the use of these as they are 
expensive and require medical administration 
with some having teratogenic and other 
unwanted toxicity problems (6). Against this 
backdrop, the development of new cost-effective 
treatments is a priority, but given that 
leishmaniasis mainly affects people living in 
developing countries, these infections are not 
deemed commercially attractive by 
pharmaceutical companies. As a result, 
leishmaniasis is largely neglected in terms of 
drug development (7). 
 
Nitroaromatic compounds encompass a wide 
range of compounds characterised by at least one 
nitro-group attached to an aromatic ring (8). 
They have been used in medicine predominately 
as antimicrobial agents, but concerns over their 
mutagenicity have led to many being withdrawn 
in Europe and USA (9-11). However, it is now 
apparent that several nitro-based compounds are 
not as toxic as initially thought (12-14) with 
retrospective analysis of nitrofurantoin clinical 
trial data coupled with cost evaluation resulting 
in calls for the reinstatement of this prodrug as a 
treatment for uncomplicated urinary tract 
infections (15). This resurgence of interest has 
led to several nitroaromatic compounds 
undergoing evaluation for treatments of 
infectious organisms including PA-824 and 
OPC-67683 against Mycobacterium 
tuberculosis, nitazoxanide against Giardia, 
Cryptosporidium and hepatitis C (16-18) and 
fexinidazole against Trypanosoma brucei and 
Leishmania donovani (19,20) while others such 
as SN23862, CB1954 and nifurtimox have 
emerged as possible anti-cancer therapies (21-
23). 
 
Most antimicrobial nitroaromatic compounds 
function as prodrugs and must undergo 
activation before producing their cytotoxic 
activity, a process mediated by nitroreductases 
(NTRs). Based on oxygen-sensitivity and flavin 
co-factors, NTRs can be broadly divided into 
two groups (24). Type I NTRs utilise NAD(P)H 
as electron donor, transferring reducing 
equivalents via an FMN co-factor, to the 
substrate in a series of sequential two electron 
reduction events. This nitroreduction does not 
involve oxygen and does not result in the 
production of reactive oxygen species, an 
activity said to be “oxygen insensitive”. In 
contrast, the type II NTRs contain FAD or FMN 
as co-factor and catalyse the one electron 
reduction of the substrates conserved nitro-group 
to generate a nitro-radical. This radical reacts 
with oxygen to produce superoxide anions with 
the subsequent regeneration of the original nitro-
compound: type II NTRs is said to be “oxygen 
sensitive” (25). The difference in NTR 
distribution is believed to underlie the specificity 
of most antimicrobial nitroaromatic prodrugs 
with type I NTRs found mainly in bacterial and 
absent from most eukarytotes, with a subset of 
fungi and protozoan parasites being the 
exceptions (26-28). Although some mammalian 
enzymes, such as NAD(P)H quinone 
oxidoreductase 1 and nitric oxide synthase, can 
mediate two electron reduction reactions under 
aerobic conditions, type II NTR activities 
predominate in most cell types (29). 
 
The aim of this study was to characterise the 
type I NTR expressed by L. major, the pathogen 
responsible for cutaneous leishmaniasis, and 
analyse the role this enzyme plays in the 
parasite. Utilising the activity, we then 
conducted biochemical and phenotypic screens 
using a library of nitrobenzylphosphoramide 
mustard (NBPM) compounds to identify 
potential leishmanicidal agents targeting the 
intracellular mammalian form of the pathogen.  
 
EXPERIME3TAL PROCEDURES 
Compounds. Nitrofurazone, nitrofurantoin, 
CB1954, coenzyme Q1 and duroquinone were 
purchased from Sigma Aldrich. Benznidazole 
and nifurtimox were provided by Simon Croft 
(London School of Hygiene and Tropical 
Medicine) and metronidazole was a gift from 
Nubia Boechat (Far Manguinhos, Rio de 
Janeiro). The NBPM structures (Tables 1 and 2) 
were fully characterized using NMR and MS and 
their purity judged to be >90 %: most were >95 
% based on LC-MS analysis (30-33). 
 
Parasite culture and genetic manipulation. L. 
major (MHOM/IL/80/Friedlin) promastigote 
form parasites were grown at 27 
o
C in M199 
medium (Life Technologies) supplemented with 
4 mM sodium bicarbonate, 40 mM HEPES 
pH7.4, 0.1 mM adenine, 0.005 % (w/v) haemin, 
2.5 U mL
-1
 penicillin, 25 µg mL
-1
 streptomycin 
and 20% (v/v) foetal calf serum. Transformed 
parasites were grown in this medium containing 
G418 (20 µg mL
-1
 on agar plates, 40 µg mL
-1
 in 
broth), blasticidin (10 µg mL
-1
) or puromycin (20 
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µg mL
-1
). L. major metacyclic form parasites 
were harvested from promastigote cultures in the 
stationary phase of growth (7-10 days old 
cultures) following agglutination of promastigote 
parasites with peanut lectin (Sigma Aldrich) (34). 
The metacyclics were used to infect 
differentiated human acute monocytic leukemia 
(THP-1) cells at a ratio of 20 parasites per 
mammalian cell. The L. major infected 
monolayers were incubated overnight at 37 
o
C 
under a 5 % (v/v) CO2 atmosphere in mammalian 
growth medium then washed with RPMI-1640, 
to remove residual parasites. L. major amastigote 
parasites were maintained in differentiated THP-
1 cells at 37 
o
C under a 5 % (v/v) CO2 
atmosphere in mammalian growth medium. 
 
For DNA transfection, L. major promastigotes 
(2 x 10
7
) in the logarithmic phase of growth were 
pelleted, resuspended in 100 µL Human T-cell 
Nucleofector
® 
solution (Lonza AG) containing 5 
µg of purified DNA and electroporated using 
program U-033 on the Nucleofector™ (Lonza 
AG). Cells were then transferred to M199 growth 
medium and allowed to recover for 20-24 hours 
at 27 
o
C. Parasites were pelleted, resuspended in 
100 µL promastigote growth medium then spread 
onto promastigote growth medium solidified 
with 1% (w/v) agar containing 1.2 µg mL
-1
 
biopterin (Sigma-Aldrich) and the appropriate 
selective agent. The plates were incubated at 27 
o
C until colonies appear. Colonies were then 
transferred into promastigote growth medium 
containing the appropriate selective agent and 
grown as described above. 
 
Mammalian cell culturing. The human acute 
monocytic leukemia cell line (THP-1) was grown 
at 37 
o
C under a 5 % (v/v) CO2 atmosphere in 
RPMI-1640 medium (PAA Laboratories Ltd) 
supplemented with 2 mM pyruvate, 2 mM 
sodium glutamate, 2.5 U mL
-1 
penicillin and 2.5 
µg mL
-1 
streptomycin, 20 mM HEPES pH 7.4 
and 10% (v/v) foetal calf serum. Differentiation 
of THP-1 towards macrophage-like cells was 
carried out using phorbol 12-myristate 13-acetate 
(20 ng mL
-1
) (PMA) (Sigma-Aldrich) (35). 
 
In vivo studies. All animal experiments were 
conducted under licence in accordance with UK 
Home Office regulations. Female BALB/c mice 
were infected by subcutaneous injection of 
2 × 10
7
 purified metacyclic parasites in 100 µL 
RPMI medium without serum into their shaved 
rump. Mice were monitored for lesion pathology 
and when observed, the diameter of each lesion 
was measured in two dimensions at a rectangular 
angle with digital callipers (Jencons Scientific 
Ltd.) and the mean diameter calculated. Three 
mice were examined for each treatment. 
 
Antiproliferative assays. All assays were 
performed in a 96-well plate format. L. major 
promastigote parasites (5 x 10
5
 mL
-1
)
 
or 
differentiated THP-1 cells (2.5 x 10
4
 mL
-1
) were 
seeded
 
in 200 µL growth medium containing 
different concentrations of nitroaromatic agent. 
After incubation at 27 
o
C for 5 days (L. major) or 
at 37 
o
C for 3 days (THP-1), 2.5 µg resazurin (20 
µL of 0.125 µg mL
-1
 stock in phosphate buffer 
saline) was added to each well and the plates 
incubated for a further 8-16 hours. Cell densities 
were determined by monitoring the fluorescence 
of each culture using a Gemini Fluorescent Plate 
Reader (Molecular Devices (UK) Ltd, 
Wokingham, UK) at an excitation wavelength of 
530 nm, emission wavelength of 585 nm and a 
filter cut off at 550 nm, and the drug 
concentration that inhibits cell growth by 50 %  
(IC50) established. 
 
Growth inhibition of luciferase expressing L. 
major amastigotes was monitored as follows. 
THP-1 cells seeded at 2.5 x 10
4
 mL
-1
 in 200 µL 
in growth medium containing PMA (20 ng mL
-1
) 
were incubated at 37 
o
C in a 5 % (v/v) CO2 
atmosphere for 3 days. Macrophage monolayers 
were copiously washed with mammalian growth 
medium then infected with purified L. major 
metacyclic cells (5 x 10
5
 cells mL
-1
) resuspended 
in 200 µL mammalian growth medium. 
Following incubation overnight at 37 °C in a 5 % 
(v/v) CO2 atmosphere, the cultures were washed 
twice in growth medium to remove non-
internalised parasites and the supernatant 
replaced with fresh growth medium containing 
drug. Drug-treated infections were incubated for 
a further 3 days at 37 
o
C under a 5 % (v/v) CO2. 
The growth medium was then removed and the 
cells lysed in 50 µL cell culture lysis reagent 
(Promega). Activity was then measured using the 
luciferase assay system (Promega) and light 
emission measured on a ß-plate counter (Perkin 
Elmer). The luminescence is proportional to the 
number of live cells. The IC50 value for each 
compound was then established. 
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Plasmids. The integrative L. major luciferase 
vector pLmRIX-luc was generated by 
sequentially cloning the L. major 5’ 
spacer/promoter rRNA and 3’ spacer rRNA 
regions either side of an expression cassette 
containing the luciferase reporter and neomycin 
resistance genes. The TcMPX polypyrimidine 
tract/splice leader addition site sequence was 
inserted between the L. major 5’ spacer/promoter 
rRNA and the luciferase gene to provide the 
genetic elements required for processing the 
reporter mRNA transcript. The resultant 
construct, pLmRIX-Luc, was linearized prior to 
electroporation into L. major promastigotes. 
 
The vectors used to delete LmTR, pKO-
LmTR-PAC and pKO-LmTR-BLA, were 
generated by sequentially cloning LmTR 
flanking sequences either side of a puromycin or 
blasticidin resistance cassette (see Fig. 3). The 
constructs were linearized then electroporated 
into L. major promastigotes. 
 
A DNA fragment encoding for the catalytic 
domain of L. major TR (LmTR) was amplified 
from genomic DNA with the primers 
ggatccCTCGACGCCGTCGAGGCCGTCG and 
aagcttCTAGAACTTGTTCCACCGCAC; lower-
case italics correspond to restriction sites 
incorporated into the primers to facilitate 
cloning. The fragment was digested with 
BamHI/HindIII then cloned into the 
corresponding sites of the vector pTrcHisC 
(Invitrogen) to form the plasmid pTrcHisC-
LmNTR. Site-directed mutagenesis was carried 
out using a Stratagene QuikChange mutagenesis 
kit (Agilent Technologies), with pTrcHisC-
LmNTR as template. Amplifications were 
performed in accordance with the manufacturer’s 
instructions using primers (Eurofins) to generate 
the desired mutation. The forward primer 
sequence was R96A 
(GCCGTCGTGCGCGACGCGTGGACGTGCC
GGCAG). The relevant substitution site, 
incorporating the required base change, is 
underlined. 
 
Protein purification. An overnight culture of E. 
coli BL21(+) containing the expression plasmid 
was diluted 1:50 in NZCYM (Sigma Aldrich) 
medium containing 100 µg mL
-1
 ampicillin and 
grown for 2-4 h at 37 °C. The culture was 
transferred to 16 °C for 30 min then protein 
expression induced by addition of isopropyl-β-d-
thiogalactopyranoside to a final concentration of 
1 mM. The culture was then incubated overnight 
at 16 
o
C. The cells were harvested then lysed in 
Buffer A (50 mM NaH2PO4, pH 7.8; 500 mM 
NaCl) containing 1 mg mL
-1
 lysozyme, 10 µg 
mL
-1
 , DNase, 10 µg mL
-1
  RNase, 1 % (w/v) 
CHAPS and a cocktail of protease inhibitors 
(Roche). The clarified supernatant was then 
applied to a pre-packed nickel-nitrilotriacetic 
acid (Qiagen) column and the column copiously 
washed with Buffer A and with Buffer A 
containing 50 mM and 100 mM imidazole. 
Recombinant protein was eluted off the column 
using Buffer A supplemented with 500 mM 
imidazole and 1 % (w/v) CHAPS. Glycerol was 
then added to a final volume of 20 % (v/v) and 
aliquots stored at -80 
o
C. Protein concentration 
was determined by the BCA assay system 
(Thermo Fisher Scientific, Cramlington, UK) and 
purity level confirmed by SDS/PAGE. 
 
Enzyme activity. LmNTR activity was measured 
spectrophotometrically using several electron 
acceptors as substrate. A standard reaction (1 
mL) containing 50 mM Tris-Cl pH7.5, 100 µM 
NADH and 100 µM electron acceptor was 
incubated at room temperature for 5 min. The 
background reaction rate was determined and the 
assay initiated by addition of the LmNTR (35 
µg). For reactions containing nitroimidazoles, 
nitrobenzylphosphoramides or most quinones, 
activity was measured by following the change in 
absorbance at 340 nm corresponding to NADH 
oxidation (ε = 6,200 M
-1
 cm
-1
) while for assays 
involving nitrofurans, the direct reduction of the 
substrate itself was monitored at 435 nm for 
nifurtimox (ε = 18,000 M
-1
 cm
-1
) or at 400 nm for 
nitrofurazone and nitrofurantoin (ε = 12,000 and 
15,000 M
-1
 cm
-1
 respectively; (36)). For CB1954, 
activity was monitored by following the change 
in absorbance at 420 nm, corresponding to 
production of the hydroxylamine (ε = 1,200 M
-1
 
cm
-1
: (37)). Data was evaluated by non-linear 
regression analysis using GraphPad Prism 5 
(GraphPad Software). 
 
Flavin characterization. The flavin co-factor 
bound to LmNTR was established by 
determining the fluorescence spectrum in acidic 
and neutral buffers (36,38). Purified protein was 
desalted and boiled for 5 min. In a total volume 
of 100 µL, clarified supernatants (90 µL) 
containing 0.5 mg NTR were mixed with 10 µL 
50 mM NaH2PO4 pH7.6 or 1 M HCl (final pH = 
2.2). The fluorescence profile for each treatment 
was then determined using a Gemini Fluorescent 
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Plate Reader (Molecular Devices Ltd) with an 
excitation λ= 450 nm and an emission λ= 480-
600 nm. The resultant patterns were compared 
with profiles obtained using FMN and FAD 
standards 
 
RESULTS 
Leishmania major expresses a functional type 
I nitroreductase. Analysis of the L. major 
genome database identified a 972 bp open 
reading frame located on chromosome 5 with 
potential to encode for a 34.7 kDa enzyme 
related to the type I nitroreductase family of 
proteins (LmNTR; GenBank accession no. 
XP_001687543). Full length LmNTR is 90 % 
identical to homologues present in L. mexicana 
(CBZ23423) and L. infantum (CAM65376) 
NTRs), 75 % to L. braziliensis NTR 
(CAM36899)) and has 50 % identity to the 
trypanosomal enzymes TcNTR (XP_810645) 
and TbNTR (XP_846343). When compared to 
bacterial counterparts such as E. coli nfsB 
(NP_415110) and Bacillus cereus NAD(P)H 
nitroreductase (NP_832770) the highest level of 
sequence identity was around 20 %. Based on 
sequence, LmNTR can be divided into two 
regions. The amino terminal portion (residues 1-
86), absent from prokaryotic sequences, is 
predicted by SignalP, PSORT II and iPSORT 
algorithms to contain a mitochondrial targeting 
signal (data not shown) while the remainder of 
the enzyme (residues 87-323) constitutes the 
catalytic domain. 
 
To evaluate whether LmNTR could function 
as a nitroreductase, the DNA sequence encoding 
for the putative catalytic domain (residues 87-
323) was expressed as a HIS-tagged protein in E. 
coli: attempts to express full length recombinant 
LmNTR failed to generate soluble protein. The 
recombinant enzyme could be readily purified 
after one round of affinity chromatography with 
elutions containing the purified HIS-tagged 
LmNTR having a yellow colouration, indicative 
of a flavoprotein (Fig. 1A). To identify the nature 
of the flavin and investigate NTR/co-factor 
interaction, recombinant LmNTR was boiled and 
the fluorescence profile of clarified supernatants 
under neutral and acidic pHs analysed (36,38) 
(Fig. 1B). Denaturation resulted in release of the 
flavin from the enzyme, indicating that the co-
factor had a non-covalent association with the 
protein backbone (39-41), while the fluorescence 
profiles under neutral and acidic pHs identified 
FMN as the flavin moiety (Fig. 1B): at neutral 
pH, and excitation at 450 nm, flavin derived 
from the parasite enzyme had a peak emission 
around 560 nm, a signal quenched in acidic 
buffers, typical of FMN and distinct from FAD. 
In the trypanosomal enzyme TcNTR an arginine 
located in the RX[S/T/A]X[R/K] motif has been 
shown to play a key role in co-factor binding 
with this region and residue conserved in 
LmNTR (42). To evaluate the importance of this 
arginine to LmNTR activity it was converted to 
alanine (R96A). Expression of the HIS-tagged 
mutant protein in E. coli resulted in recombinant 
protein but at levels considerably lower than that 
obtained with the wild type enzyme. The mutated 
enzyme remained in insoluble fractions despite 
several attempts to optimise expression and 
purification conditions (data not shown).  
 
To investigate its substrate specificity, HIS-
tagged LmNTR activity was monitored under 
aerobic conditions by following NADH or 
NADPH oxidation at 340 nm, or, when a 
compound’s absorbance spectra precluded this, 
by following reduction of the substrate itself 
(Fig. 2A). This demonstrated that the 
recombinant leishmanial enzyme functioned as 
typical type I NTR, able to catalyze the reduction 
of a wide range of nitroaromatics and quinones 
in an oxygen insensitive fashion (Table 3). When 
the specificity constants (kcat/KM) generated by 
these substrate were compared LmNTR showed 
a preference for quinone compounds: the kcat/KM 
values exhibited by HIS-tagged LmNTR toward 
the ubiquinone 5 (2.0 x 10
4
) was an order of 
magnitude greater than for CB1954 (4.6 x 10
3
) 
and benznidazole (2.5 x 10
3
). Interestingly, 
recombinant LmNTR could use both NADPH 
and NADH as electron donors although when 
using fixed concentrations of benznidazole (100 
µM) and NADPH or NADH (100 µM) activity 
values indicated a preference for NADH: under 
these conditions LmNTR had a specific activity 
of 110 nmol NADH oxidised min
-1
 mg
-1
 as 
compared to 50 nmol NADPH oxidised min
-1
 
mg
-1
. Using benznidazole (100 µM) as substrate, 
HIS-tagged LmNTR had an apparent Km for 
NADH of 76 µM, similar to the values reported 
for TbNTR and TcNTR (71 and 86 µM, 
respectively) (42). 
 
To examine how recombinant LmNTR 
interacts with NADH, assays were carried out 
using various concentrations of reductant against 
a fixed concentration of benznidazole (Fig. 2B). 
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For this substrate, double-reciprocal plots were 
linear at all concentrations of electron acceptor, 
with the slopes remaining parallel. When the 
converse experiments were performed using a 
fixed concentration of NADH and various 
amounts of benznidazole, a similar pattern of 
parallel slopes were observed (Fig. 2B). These 
patterns are characteristic of a ping-pong 
mechanism of kinetics, typical for 
oxidoreductase cascades. However, when 
benznidazole or NADH levels were above 200 
µM non-competitive substrate inhibition was 
observed indicating that this mechanism of 
kinetics only occurs over a limited electron 
donor/acceptor concentration range (Fig. 2C). 
 
Functional analysis of Lm3TR in L. major. To 
investigate whether the leishmanial type I NTR 
can activate nitroaromatic drugs in the parasite 
itself, we developed L. major LmTR 
heterozygotes and then examined the 
susceptibility of the cells to nifurtimox. DNA 
fragments corresponding to the regions 
immediately upstream and downstream of 
LmTR were amplified from genomic DNA and 
cloned sequentially either side of cassettes 
containing puromycin or blasticidin resistance 
markers. The constructs were linearised and the 
purified fragments transformed into L. major 
promastigotes with clones selected on agar plates 
containing puromycin or blasticidin. Southern 
hybridisation of genomic DNA showed that one 
LmTR allele could be disrupted generating 
heterozygous parasites (LmTR
+/-
PAC or 
LmTR
+/-
BLA) (Fig. 3), with no obvious effect 
on parasite growth or ability to differentiate into 
infective metacyclic forms (Fig. 4A). To evaluate 
whether reduction of the LmTR copy number 
affected resistance to nitroheterocyclic drugs, 
LmTR
+/-
BLA promastigote parasites were grown 
in the presence of nifurtimox (Fig. 4B). From the 
resultant dose response curves, the IC50 value of 
the heterozygote line was shown to be 
approximately 2-fold higher than wild type 
parasites: L. major wild type cells exhibited an 
IC50 value of 6.28 ± 0.04 µM as compared to 
11.50 ± 0.60 µM for the LmTR
+/-
 line. 
 
Attempts (16 independent transformations) to 
generate LmTR null mutant lines failed, leading 
us to speculate that the protein is essential to 
promastigote form parasites. To confirm this we 
constructed a range of pTEX- and pIR-SAT1-
based episomal and integrative complementation 
vectors designed to facilitate expression of 
LmNTR or variants tagged at the carboxyl 
terminal with an epitope derived from the human 
c-myc protein. Attempts (20 independent 
transformations) to generate parasites lines 
containing an ectopic copy of LmTR failed, 
leading us to postulate that expression of 
elevated NTR levels was also deleterious to L. 
major promastigotes. Even when using 
“amastigote-specific” integrative vectors, where 
LmTR expression was placed under the control 
of the well characterised Leishmania regulatory 
genetic element (the amastin 3’ UTR (43)), no 
recombinant parasites were obtained: the 
“amastigote-specific” expression system was 
validated using constructs expressing luciferase 
where the reporter activity under the control of 
the amastin 3’ UTR was only 2-10 fold above 
background while in the absence of this 
regulatory genetic element reporter activity 
>1000 fold higher (data not shown). This toxicity 
may be in part due to LmNTRs amino terminal. 
To facilitate localisation, attempts (6 independent 
transformations) to generate L. major 
promastigotes expressing the amino terminal 
extension (residues 1-85) of LmNTR fused at its 
carboxyl terminal with GFP or RFP failed 
despite using episomal or integrative expression 
vectors (data not shown). 
 
To aid the characterisation of L. major 
LmTR heterozygotes, LmTR
+/-
BLA cells were 
transformed with a DNA fragment that integrates 
into the L. major rRNA promoter/spacer region 
and facilitates expression of luciferase. 
Following selection, the luminescence activity of 
clonal parasite extracts was shown to be >10
6
 
fold above background, comparable to lysates 
generated from luciferase expressing wild type 
cells. These parasites also exhibit promastigote 
growth and metacyclogenesis rates equivalent to 
wild type/non-luciferase expressing LmTR 
heterozygotes (data not shown). Metacyclic form 
parasites from luciferase tagged LmTR
+/-
 
heterozygote and wild type promastigote cultures 
in the stationary phase of growth were then 
purified and used to infect differentiated THP-1 
macrophage cells. Over the following 4 days, 
total cell extracts were generated from 
parasite/mammalian cultures and the luciferase 
activity determined (Fig. 5A). After correcting 
for background luminescence (lysed, uninfected 
macrophages), the reporter signal generated from 
tagged wild type amastigotes increased, reaching 
a plateau by day 4 post-infection. In contrast, 
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LmTR
+/-
 heterozygote cultures exhibited 
luminescence values equivalent to background. 
This indicates that disruption of one LmTR 
allele results in haploid insufficiency such that L. 
major LmTR heterozygote amastigotes are 
unable to establish themselves in tissue cultured 
mammalian macrophages. 
 
To determine whether the in vitro amastigote 
proliferation defect translates to problems with in 
vivo growth, BALB/c mice were infected with 
purified wild type or LmTR
+/-
 heterozygote L. 
major metacyclic cells. Over a 97 day period, the 
presence and size of any lesion was monitored 
(Fig. 5B). All 3 mice infected with wild type 
parasites developed lesions by day 31 with the 
lesions gradually increasing in size: all mice 
were euthanized at day 51. Interestingly, all mice 
infected with LmTR
+/-
 heterozygote cells 
presented no signs of lesion until day 98, where 
single mouse developed a lesion, with the 
remaining mice developing pathologies 24 days 
latter (day 122). In all cases the lesion size 
gradually increased until day 128 when all mice 
were euthanized. The altered kinetics in 
pathology development strongly indicates that 
LmNTR function is important in establishing a L. 
major infection in vivo with the heterozygote line 
struggling to grow as amastigote form parasites 
in BALB/c mice. 
 
Exploiting the pro-drug activating properties 
of the Leishmania type I 3TR. We have 
previously shown that NBPM compounds are 
effective NTR-activated trypanocidal agents 
(36). As an initial screening strategy to determine 
the potential for exploiting LmNTR activity in 
prodrug activation, we determined whether HIS-
tagged LmNTR displayed activity toward a 
library of NBPMs by monitoring the change in 
absorbance at 340 nm, corresponding to NADH 
oxidation (Fig. 6A). In total, 22 compounds were 
screened: 8 structures where either a p-
nitrobenzyl group or an o- nitrophenylacetamido 
group is attached to cyclophosphamide (Table 1) 
and 14 structures where phosphoramide mustard 
is linked to a nitrobenzyl group with various 
substituents (Table 2).  Based on the preliminary 
biochemical screen, the compounds could be 
divided into those that were not LmNTR 
substrates (activity <20 nmol NADH oxidised 
min
-1
 mg
-1
), those that stimulated a moderate 
activity (between 20-50 nmol NADH oxidised 
min
-1
 mg
-1
) and those that were readily 
metabolised by the parasite enzyme (>50 nmol 
NADH oxidised min
-1
 mg
-1
). Using this as a 
crude measure, 3 cyclic NBPMs (LH5, 6 and 12) 
were evaluated as moderate substrates while the 
remaining 5 showed little/no activity. In contrast, 
most of the acyclic structures were metabolised 
by recombinant LmNTR with 6 (LH27, 31-34 
and 37) showing high levels of activity. Of those 
substrates generating the higher activities, 5 
contained at least one halogen linked to the nitro-
substituted benzene ring. 
 
To determine whether there was a correlation 
between biochemical activity and parasite 
killing, all NBPMs were initially screened for 
leishmanicidal activity against L. major 
promastigote and amastigote forms. Out of the 
22 compounds, 15 were shown not to affect 
growth of the insect stage pathogen at 30 µM 
with all except one (LH19) also having no effect 
on amastigote growth at a concentration of 10 
µM (Table 4). For the remaining leishmanicidal 
compounds, growth inhibition assays were 
performed to determine their IC50 values (Table 
4). Many of these displayed appreciable 
leishmanicidal properties, with 5 NBPMs (LH31-
34 and 37) having significant activity (IC50’s <10 
µM) against both parasite forms. These 5 
compounds correspond to structures previously 
designated “good” LmNTR substrates (Fig. 6). 
 
The 8 compounds identified as having 
appreciable leishmanical activity were assayed 
for cytotoxicity against differentiated THP-1 
cells from which the selective index (SI) (IC50 
against the mammalian line/IC50 against the 
amastigote parasite) was then determined (Table 
4). In all cases, no toxicity to the mammalian line 
was observed at concentrations up to 100 µM. 
For three of the halogenated compounds 
identified as being preferred LmNTR substrates 
and having anti-parasitic activity against both L. 
major forms (LH32-34), SI values against 
amastigote parasites of >100 were observed. 
 
To demonstrate that NTR plays a role in 
NBPM prodrug activation within the parasite 
itself, the susceptibility of L. major LmTR
+/-
BLA heterozygote promastigotes to LH33 and 
LH34 was investigated (Fig. 6B). For both 
compounds, cells with reduced levels of the 
nitroreductase were up to 3-fold more resistant to 
the agent than wild type controls: L. major wild 
type cells exhibited IC50 values of 4.73 ± 0.29 
and 3.70 ± 0.40 µM toward LH33 and LH34, 
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respectively with LmTR
+/-
 heterozygote cells 
displaying values of 7.66 ± 0.23 and 12.14 ± 0.84 
µM against these two compounds. 
 
Based on our findings, NBPMs that contain 
the phosphoramide mustard as part of an acyclic 
structure and have halogen substituents on the 
nitrobenzyl ring are the most readily metabolised 
by the LmNTR enzyme and represent the most 
potent agents against both L. major 
promastigotes and amastigotes. Some (LH32, 33 
and 33) have IC50 values of 1 µM or less against 
the intracellular stage without inducing 
mammalian cell toxicity. 
 
DISCUSSIO3 
Activation of most antimicrobial 
nitroaromatic prodrugs occurs through reactions 
catalysed by type I NTRs (24,26). This group of 
enzymes were believed to be restricted to 
bacteria but it is now apparent that they are also 
expressed by several ‘lower’ eukaryotes 
including fungi and protozoan parasites (20,26-
28). Interestingly, type I NTRs appear to be 
absent from ‘higher’ eukaryotes including 
humans, and it is believed that this difference in 
the enzymes’ distribution underlies the 
antimicrobial selectivity of many nitroaromatic 
prodrugs. Here, we demonstrate that L. major 
expresses a type I NTR that possesses many 
biochemical characteristics displayed by its 
bacterial counterparts. Functional studies 
revealed that this activity is essential for the 
growth of parasite forms found in the insect 
vector and extremely important to the 
intracellular forms found in mammalian cells, 
indicating that this prodrug activating enzyme is 
a drug target in its own right. 
 
The activity of all type I NTRs, irrespective of 
their origin, is dependent on FMN with the 
enzyme/flavin interaction occurring via a non-
covalent linkage, features shared by LmNTR 
(Fig. 1): HIS-tagged LmNTR activity was 
associated with yellow coloured fractions, 
boiling released the associated co-factor from the 
protein backbone with clarified supernatants 
exhibiting fluorescence profiles under acidic and 
neutral pH’s identical to that observed with FMN 
(Fig. 1). For the leishmanial enzyme, the co-
factor acts an intermediary, accepting reducing 
equivalents derived preferentially from NADH 
then denoting these to a range of nitroaromatic 
and quinone based substrates (Table 3). While 
catalysing this transfer, HIS-tagged LmNTR 
displays a ping-pong type of kinetics, typical of 
oxidoreductases (Fig. 2). In TcNTR, co-factor 
binding is mediated by a specific arginine residue 
at position 90 present in a conserved motif. This 
amino acid (R96 in LmNTR) plus the adjacent 
region is present in NTR from L. major. 
Attempts to express a mutated version of the 
leishmanial enzyme (R96A) failed to generate 
soluble, active protein suggesting that the non-
covalent FMN binding to the protein backbone 
may be important in the correct folding of 
LmNTR.  
 
Based on its substrate preferences (Table 3) 
and subcellular localisation, as inferred from its 
sequence, LmNTR may function as a 
mitochondrial NADH:quinone oxidoreductase. 
In the mitochondria of most eukaryotes, 
oxidation of NADH to NAD
+
 is normally 
mediated by complex I of the electron transport 
chain. This activity serves to translocate protons 
across the organelle’s inner membrane with the 
concomitant reduction of ubiquinone to 
ubiquinol. Ubiquinol then drives the cytochrome-
dependent respiratory chains that help to form 
the proton motive force which ultimately leads to 
ATP synthesis. In contrast to bloodstream 
dwelling trypanosomes all replicative 
Leishmania forms express functional 
cytochrome-dependent electron transport chains 
suggesting that energy production occurs via the 
well documented route within these parasites 
(44-46). However, the role played by the 
Leishmania complex I in driving these cascades 
is unclear. Inhibitor studies indicate that these 
protozoa possess an atypical complex I with 
bioinformatic studies revealing a subunit 
composition distinct from that found in other 
eukaryotic organisms (44,47). As LmNTR 
appears to fulfil an analogous role to the 
leishmanial complex I, with both functioning as 
NADH:quinone oxidoreductases, these may act 
in concert to help maintain the NADH/NAD
+
 
balance within the parasite mitochondrion. 
 
The endogenous function of LmNTR is 
essential to replicating L. major: LmTR could 
not be deleted from non-infectious promastigote 
parasites with the heterozygotes unable to 
establish an infection in cultured macrophages 
and struggled to generate lesion pathology in 
mice (Fig. 5). This is similar to the situation in L. 
donovani but distinct from that observed in 
trypanosomes where the essential nature of NTR 
is only apparent in the replicating forms present 
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in the mammalian host (26,48). As we were 
unable to express elevated levels of LmNTR in 
L. major heterozygote and wild type 
promastigotes the appropriate complementation 
experiments could not be performed. 
Intriguingly, complementation studies could be 
conducted using L. donovani promastigotes (48): 
L. donovani TR null mutants could be 
generated only in the presence of an ectopic copy 
of L. major TR. The deleterious effect of 
expressing LmNTR at elevated levels may not be 
due to the enzymatic activity of the protein itself 
but could reflect an inherent problem associated 
with the amino terminal extension. Therefore, 
when expressed at levels higher than that found 
in wild type (and heterozygote) the LmNTR 
extension may interfere with mitochondrial 
transporter function or could interact with other 
essential cellular components thereby inhibiting 
their activities. 
 
Nitrobenzylphosphoramide mustards are a 
novel class of compounds incorporating chemical 
motifs present in several DNA alkylating, anti-
cancer agents (30-33). They contain a nitrogen 
mustard moiety coupled to a nitrobenzyl ring via 
a phosphoramide linker and are designed to 
function as prodrugs specifically tailored to 
undergo activation in reactions catalysed by type 
I NTRs. Here, we performed a structure activity 
relationship (SAR) on a library of NBPMs 
employing biochemical and leishmanicdal 
screens (Fig. 6 and Table 4). When using a group 
of NBPMs where the phosphoramide linker was 
part of a cyclic structure (Table 1), recombinant 
LmNTR protein was shown to metabolise some 
(3 out of 8) at reasonable rates but this failed to 
translate into an anti-parasitic activity. Screens 
involving NBPMs where the phosphoramide was 
part of a linearised linker (Table 2) yielded 
similar results for 6 out of 14 compounds with 
the remaining NBPMs being effective LmNTR 
substrates and displaying leishmanicidal effects. 
When comparing the anti-parasitic properties 
exhibited by the 8 most potent NBPMs against 
the two replicative L. major life cycles stages, 
intracellular amastigote parasites were generally 
more susceptible to the agent under study than 
the promastigote form: LH33 had IC50’s of 5.88 
± 0.28 and 0.21 ± 0.07 µM against promastigote 
and amastigote form parasites, respectively, 
while LH34 exhibited values of 3.10 ± 0.28 and 
0.77 ± 0.12 µM. To conclusively demonstrate 
that the LmNTR plays a role in NBPM activation 
in the parasite itself, the susceptibility of L. 
major LmTR
+/-
 heterozygous cells to LH33 and 
LH34 was evaluated. In both cases, reduction of 
the LmTR gene copy number resulted in a 
resistance phenotype in agreement with 
observation made using recombinant 
trypanosomes and L. donovani towards other 
nitroaromatics (Fig. 6) (26,48). As mammalian 
cells lack a type I NTR activity, they should be 
less susceptible to prodrugs that rely on this 
mechanism of activation. When the 8 most 
potent leishmanicidal NBPMs were screened 
against the macrophage line in which the 
intracellular parasites were cultured, no 
cytotoxicity was observed at values up to 100 
µM) (Table 4). In terms of relative toxicity 
values, the 2 agents showing the highest potency 
against amastigote cells were >476 (LH33) and 
>143 (LH34) more toxic to the parasite than this 
particular mammalian line. 
 
We have now shown that L. major expresses a 
type I NTR which in the related trypanosomal 
parasites activates the clinically used prodrugs 
nifurtimox and benznidazole (26,49,50). The 
leishmanial enzyme displays characteristics 
typical of this group of oxidoreductase being able 
to non-covalently bind with FMN and, through a 
ping-pong mechanism, utilises NADH to reduce 
a wide range of nitroaromatic and quinones. We 
exploited this activity and identified several 
leishmanicidal NBPM compounds that have 
little/no cytotoxicity in mammalian cells. Based 
on substrate preference, the L. major type I 
NTRs can be regarded as NADH:quinone 
oxidoreductase, with this activity being 
important to the replicative parasite forms found 
in the insect and mammalian host. Therefore, our 
data indicate that the leishmanial enzyme can be 
used in drug development in two ways, either as 
an activator of new, nitroaromatic or quinone-
based prodrugs and through the use of inhibitors 
targeting this essential activity. Additionally, 
these two approaches could be complementary: 
an L. major strain showing resistance to drugs 
developed to inhibit LmNTR could theoretically 
be sensitive or even hypersensitive to prodrugs 
activated by this leishmanial enzyme, and vice 
versa. 
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FIGURE LEGE3DS 
 
Figure 1 Leishmanial 3TRs contain FM3 as a cofactor. (A) Coomassie-stained SDS-PAGE gel 
(10%) containing purified, recombinant LmNTR (lane 2). Lane 1, size standards. (B) Fluorescence 
spectra of FMN and FAD (both 50 µM) and of supernatant from boiled and purified recombinant 
LmNTR (0.5 mg) at pH 7.6 (solid line) and pH 2.2 (dashed line) with excitation at 450 nm and 
emission between 480 and 600 nm. All the fluorescence analyses were carried out in triplicate; the 
profiles are derived from the mean values. 
 
Figure 2. Investigation of the kinetic properties of leishmanial type I nitroreductase toward 
benznidazole. (A) Postulated scheme for the L. major type I nitroreductases (NTR) mediated 
reduction of benznidazole (BNZ) by the using NADH as an electron donor. “Red” represents the 
reduced form and “oxid” represents the oxidized form of benznidazole. The oxidized (FMN) and 
reduced (FMNH2) forms of the flavin cofactor are indicated. (B, left) Interaction of LmNTR with 
NADH (reaction I). Activity was assayed by monitoring the oxidation of NADH (30 to 100 µM) in 
the presence of benznidazole (50 µM [▲], 75 µM [●], and 100 µM [■]) and HIS-tagged LmNTR (35 
µg). (Right) Interaction of LmNTR with benznidazole (reaction II). Activity was assayed by 
monitoring the oxidation of NADH (70 µM [▲], 80 µM [●], and 100 µM [■]) in the presence of 
benznidazole (20 to 100 µM) and HIS-tagged LmNTR (35 µg). (C) Inhibition of LmNTR activity by 
high concentrations of NADH or benznidazole. In reaction I, a fixed concentration of benznidazole 
(100 µM) was reduced by HIS-tagged LmNTR (35 µg) using various concentrations of NADH (50 to 
400 µM). At high NADH levels (>200 µM), substrate inhibition was observed. In reaction II, a fixed 
concentration of NADH (100 µM) was oxidized by HIS-tagged LmNTR (35 µg) using various 
concentrations of benznidazole (50 to 400 µM). At benznidazole concentrations above 200 µM, 
substrate inhibition was observed. All assays were initiated by the addition of the parasite enzyme. 
LmNTR activity is expressed as µmol NADH oxidized min
-1
 mg protein
-1
, while [NADH] and 
[benznidazole] are expressed in µM. 
 
Figure 3. Disruption of Lm TR in L. major. (A) Diagram of the LmTR alleles and the effects of 
gene disruption. 5’ and 3’ untranslated regions (dashed line) immediately upstream and downstream 
of LmTR (black box) were amplified and cloned sequentially either side of a puromycin (pac; dark 
grey box) or blasticidin (bla; white box) cassette containing T.brucei tubulin intergenic elements 
required for processing of mRNA (light grey boxes). The position of the predicted ApaI (A) sites plus 
the band sizes (in kbp) obtained after hybridisation are shown. (B) Autoradiographs of ApaI digested 
genomic DNA from L, major (lane 1), LmTR
+/-
PAC and LmTR
+/-
BLA heterozygous clones (lanes 2 
and 3 respectively). Blots were hybridized with labelled 5’ untranslated region of LmTR. Sizes given 
are in kbp. 
 
Figure 4. Promastigote growth and metacyclogenesis of the L. major Lm TR heterozygous line. 
(A) L. major wild type (square; solid line) and LmTR
+/-
BLA heterozygote (circle; dotted line) 
promastigote parasites growth was monitored until cultures were in the stationary phase of growth 
(time = 240 h). At 120 h onward, the number of metacyclic form parasites in wild type (triangle; solid 
line) and LmTR
+/-
BLA heterozygote (cross; dotted line) promastigote culture was determined 
following purification by agglutination. The data is expressed as % metacyclics load in the total L. 
major population. All curves shown are derived from a single data set and are representative of 
experiments performed in triplicate. (B). Dose response curves of nifurtimox on L. major wild type 
(wt) and LmTR
+/-
BLA heterozygote (TR
+/-
) promastigotes. Data are means from four experiments ± 
standard deviations, and the differences in susceptibility were statistically significant (P < 0.01), as 
assessed by Student’s t test. 
 
Figure 5. Disruption of a single Lm3TR allele affects infectivity. (A) Purified L. major wild type 
(wt) and LmTR
+/-
BLA heterozygote (TR
+/-
) metacyclic form parasites engineered to express 
luciferase were used to infect differentiated THP-1 cells. Over a 4 day post infection period, extracts 
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were generated from each cell line and the luciferase activity determined. Following background 
correction, the luciferase activity was plotted against time. All curves shown are derived from a single 
data set and are representative of experiments performed in triplicate. (B) Purified L. major wild type 
(wt) and LmTR
+/-
BLA heterozygote (TR
+/-
) metacyclic form parasites were inoculated into the 
rump of BALB/c mice. Periodically, the diameter of the lesion was measured. For each cell line, three 
mice were infected and the data is expressed as the mean lesion size (in mm) ± standard deviation. For 
the heterozygote infections, the lesion sizes on days 98 and 114 are derived from a single mouse as 
the wounds present on other animals could not be accurately determined.  
 
Figure 6. Evaluating nitrobenzylphosphoramide mustards as Lm3TR substrates. (A) The 
activity of purified HIS-tagged LmNTR was assessed by using various NBPMs (100 µM) as substrate 
at a fixed concentration of NADH (100 µM). The values shown are the means of data from three 
experiments ± standard deviations. LmNTR activity was deemed to be high if it was >50 nmol NADH 
oxidized min
-1
 mg
-1
 (dotted line). The activity obtained when using nifurtimox (NFX) as a substrate is 
also shown. (B). Dose response curves of L. major wild type (wt) and LmTR
+/-
BLA heterozygote 
(TR
+/-
) promastigotes to LH33 and LH34. Data are means from four experiments ± standard 
deviations. 
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TABLES 
 
Table 1: Structure of cyclic nitrobenzylphosphoramide mustards. 
 
A 
X
P
O
N
CH2CH2Cl
CH2CH2Cl
O2N
Y
 
 
B 
X
P
O
N
CH2CH2Cl
CH2CH2Cl
H
N
YO
NO2  
compound structure diastereomer 
 
Compounds based on A   
LH3 X=O; Y=NH cis 
LH4 X=O; Y=NH trans 
LH5 X=NH; Y=O cis 
LH6 X=NH; Y=O trans 
LH12 X=NH; Y=NH cis  
LH13 X=NH;Y=NH trans 
   
Compounds based on B   
LH8 X=O; Y=NH cis 
LH9 X=O; Y=NH trans 
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Table 2: Structure of acyclic nitrobenzylphosphoramide mustards. 
 
 
O X
Y
O
N
CH2CH2Cl
CH2CH2Cl
R3 R1
R2
R4
R5 Z  
 
compound structure 
 
LH7 R3=NO2; X=P; Y=NH2; R1=R2=R4=R5=Z=H 
LH14 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2=R4=R5=H 
LH15 R5=NO2; X=P; Y=NH2; R1=R2=R3=R4=Z=H 
LH16 R4=NO2; X=P; Y=NH2; R1=R2=R3=R5=Z=H 
LH17 R3=NO2; R5=OCH3; X=P; Y=NH2; R1=R2=R4=Z=H 
LH18 R3=NO2; R4=OCH3; X=P; Y=NH2; R1=R2=R5=Z=H 
LH19 R3=NO2; R4=CH3; X=P; Y=NH2; R1=R2=R5=Z=H 
LH24 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2= R4=R5=H 
LH27 R3=NO2; X=C; R1=R2= R4=R5=Z=H 
LH31 R2=F; R3=NO2; X=P; Y=NH2; R1=R4=R5=Z=H 
LH32 R1=F; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH33 R1=CF3; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH34 R1=Cl; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH37 R1=R5=F; R3=NO2; X=P;  Y=NH2; R2= R4=Z=H 
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Table 3: Substrate specificity of Lm3TR. The apparent Vmax and KM values of HIS-tagged LmNTR 
toward various nitroaromatic and quinone-based substrates were determined in the presence of NADH 
(Material and Methods). The kcat/KM (the ‘specificity constant’) was then determined providing a 
useful ratio for comparing the relative rates of LmNTR activity on various substrates 
 
compound apparent KM 
(µM) 
apparent Vmax 
(nmol min
-1
 mg
-1
) 
kcat/KM 
(M
-1
s
-1
) 
Nitroimidazole 
benznidazole 
 
22.0 ± 0.4 
 
78.7 ± 1.0 
 
2.5 x 10
3
 
metronidazole 2.4 ± 0.0 17.9 ± 0.0 5.2 x 10
3
 
Nitrofuran 
nifurtimox 
 
9.7 ± 1.1 
 
50.9 ± 7.0 
 
3.7 x 10
3
 
nitrofurazone 4.7 ± 0.6 68.3 ± 10.0 1.0 x 10
4
 
nitrofurantoin 3.9 ± 0.5 56.7 ± 8.0 1.0 x 10
4
 
 
Nitrobenzyl 
CB1954 
 
 
13.1 ± 0.1 
 
 
85.9 ± 1.0 
 
 
4.6 x 10
3
 
LH32 28.8 ± 2.7 100.7 ± 10.0 2.5 x 10
3
 
LH33 8.2 ± 1.0 114.2 ± 15.0 9.8 x 10
3
 
LH37 7.1 ± 0.4 71.7 ± 5.0 7.1 x 10
3
 
    
Quinone 
duroquinone 
 
9.8 ± 0.3 
 
140.6 ± 5.0 
 
1.0 x 10
4
 
coenzyme Q1 5.1 ± 0.4 145.2 ± 11.0 2.0 x 10
4
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Table 4: Susceptibility of L. major and differentiated THP-1 cells to nitrobenzyl phosphoramide 
mustards
a
 
compounds L. major IC50 (µM) differentiated THP-1 
IC50 (µM)
c
 
selective 
toxicity
d
 promastigotes
b
 amastigotes
c
 
nifurtimox 
 
6.28 ± 0.04 2.15 ± 0.01 >100.00 >47 
LH3-9 LH12-15; 
LH17-18; LH24 
>30.00 >10.00 nd nd 
 
LH16 
 
15.60 ± 1.13 
 
2.75 ± 0.40 
 
>100.00 
 
>36 
LH19 >30.00 4.72 ± 0.55 >100.00 >21 
LH27 16.23 ± 0.29 4.65 ± 0.15 >100.00 >22 
LH31 9.05 ± 0.56 7.00 ± 0.40 >100.00 >14 
LH32 4.72 ± 0.23 1.09 ± 0.21 >100.00 >92 
LH33 5.88 ± 0.28 0.21 ± 0.07 >100.00 >476 
LH34 3.10 ± 0.28 0.77 ± 0.12 >100.00 >143 
LH37 1.29 ± 0.08 2.17 ± 0.27 >100.00 >46 
 
a
 nd, not determined. 
b
 Data are means from 4 experiments ± standard deviation. 
c
 Data are means 
from 3 experiments ± standard deviation. 
d
 The therapeutic index of a compound was calculated as a 
ratio of the IC50 against differentiated THP-1 cells to the IC50 against amastigote parasites.  
